Spring 2025 funding cycle: Applications available until Monday, March 3.
- Call opens: Thursday, January 30, 2025
- Deadline: Monday March 3, 2025 (2:00 pm PST)
- Funding results: Available before end of May 2025
Amount available: $50,000 in direct costs for 1 year
Apply through the UCSF Resource Allocation Program (RAP) portal
The CFAR Mentored Scientist Award (our primary award program) is a mentoring and training grant targeted toward early stage (either at a senior stage of clinical or postdoctoral training or junior faculty) investigators at UCSF or affiliated partner institutes in the conduct of an HIV research project. These awards are designed to acquire preliminary data and research skills to prepare investigators for a future grant effort. Applicants for this award must indicate a faculty research mentor(s) who will commit to guiding the applicant throughout the duration of the proposed project.
Designation of Mentor
All Mentored award applications from individuals at the Assistant Professor level or below require an HIV research mentor. Mentors can, but are not required to, have supervisory authority over the applicant. CFAR requires your research mentor’s support to advise and guide the research portion of your application before submitting it to RAP.
Of high interest to CFAR are investigations ranging from basic pathogenesis to clinical outcomes in the research areas of HIV/aging and inflammation, latency, cure, vaccines, co-infections, HIV in women, implementation science, and research related to HIV-infected and HIV-impacted Bay Area populations. Projects must be within NIH’s HIV/AIDS research high or medium priority areas. Projects in closely related areas (e.g. TB, HCV, drug use, etc.) must be clearly linked to HIV in order to be eligible for CFAR funding.
The award amount is $50,000 in direct costs for one year.
CFAR requests that applicants review the NIAID HIV Language Guide as they prepare their proposals so that they can follow best practices on language for communicating respectfully about HIV and related topics, including the use of person-first, non-stigmatizing language. Please contact us if you have any questions about this request.
For more detailed information about this RFA, please see the RAP Portal.
To see examples of previously funded projects, see the list below.
Mentored Science Awardees
128 Awards
-
Clonal Hematopoiesis and CV Risk in Patients Living with HIV
Clonal Hematopoiesis and CV Risk in Patients Living with HIV
Abstract
Antiretroviral therapy (ART) has transformed HIV into a chronic disease, dramatically extending the lifespan of people living with HIV (PLWH). As such, the burden of cardiovascular disease (CVD) in PLWH is expected to increase significantly as the current generation ages. PLWH have been shown to be at increased risk for CVD, including sudden cardiac death, acute myocardial infarction, stroke, peripheral arterial disease, and heart failure. The mechanism of elevated risk of CVD in HIV remains unknown, but chronic inflammation is suspected to play a role.
-
Engagement and retention in tuberculosis care services among people living with HIV in Lusaka, Zambia: Does gender matter?
Engagement and retention in tuberculosis care services among people living with HIV in Lusaka, Zambia: Does gender matter?
Abstract
Tuberculosis (TB) remains the leading cause of death among people living with HIV (PLHIV) worldwide. Improving the diagnosis and treatment of TB in ‘high-risk’ groups will be critical to the Global End TB strategy. It is not well appreciated that men account for two-thirds of the 9 million new adult TB cases globally. Similar to PLHIV, men represent a high-risk TB population as they are also more likely to develop TB, remain undiagnosed, and experience poor TB-related outcomes.
-
Characterization of HIV multiple splicing stage aiming to efficiently reverse HIV latency
Characterization of HIV multiple splicing stage aiming to efficiently reverse HIV latency
Abstract
Despite combination antiretroviral therapy (cART), HIV persists as an integrated provirus in latently infected cells, preventing cure. Recent work in our laboratory suggests that HIV latency in circulating CD4+ T cells is likely due to a series of reversible blocks to HIV transcriptional elongation, distal transcription/polyadenylation, and especially splicing.
-
Identifying Reasons for Late-Diagnosis of HIV: An Academic-Community Partnership to Improve Health Outcomes
Identifying Reasons for Late-Diagnosis of HIV: An Academic-Community Partnership to Improve Health Outcomes
Abstract
In the United States, nearly a third of those diagnosed with HIV were diagnosed late, meaning that they were diagnosed with AIDS at the same time as or within one year of their HIV diagnosis. Late HIV diagnosis is associated with poor treatment outcomes and, in turn, less viral suppression, greater transmission of HIV to those who are not infected, and increased HIV-related morbidity and mortality. The United States’ goal of reducing HIV in part by increasing peoples’ awareness of their HIV status cannot be achieved without addressing late diagnosis.
-
Postpartum Adherence to HIV treatment and Prevention of Mother to Child Transmission Strategies: The Implications of Transitions Among Women Living with HIV in Kisumu County, Kenya.
Postpartum Adherence to HIV treatment and Prevention of Mother to Child Transmission Strategies: The Implications of Transitions Among Women Living with HIV in Kisumu County, Kenya.
Abstract
Prevention of mother to child transmission of HIV is now possible through evidence-based strategies that reduce the risk of transmission to less than 2%. However, the effectiveness of these strategies depends on the mothers living with HIV adhering to HIV treatment and being retained in care. Difficulties in adhering to prevention strategies has resulted in mother to child transmission (MTCT) rates that remain unacceptably high. In Kenya, MTCT rates are still estimated at around 14% with over 6,000 newly infected children in 2016.
-
Structure-based Tat/TAR inhibitor screening for the development of novel treatments and a cure for HIV/AIDS
Structure-based Tat/TAR inhibitor screening for the development of novel treatments and a cure for HIV/AIDS
Abstract
38 million people are currently living with HIV/AIDS. Although the progress in developing antiretroviral therapies (ART) has been enormous, ART is too expensive or inaccessible for a large fraction of infected individuals, and requires lifelong adherence to a treatment regimen. An HIV cure would address many of these problems, but is still missing.
-
Improving clinical care for HIV-infected transplant patients by innovations in rejection diagnostics
Improving clinical care for HIV-infected transplant patients by innovations in rejection diagnostics
Abstract
HIV-infected patients undergoing kidney transplantation are a unique patient subset with significantly increased episodes of graft rejection compared to non-infected transplant recipients. Biomarker development for monitoring of transplant rejection is a critically unmet need, particularly in HIV-infected individuals. Epigenetic mechanisms, including changes in DNA 5-methylcytosine (5mC), contribute to AR and can be used for HIV-infected kidney transplant recipients (HIVKT). screening.
-
Untangling the Gordian knot of HIV, stress, and cognitive function via a mixed methods study of food insecurity
Untangling the Gordian knot of HIV, stress, and cognitive function via a mixed methods study of food insecurity
Abstract
Food insecurity (FI) impacts health via biological, psychological, behavioral, and social-structural pathways. As such, the study of FI in the etiology of poor health has helped illuminate synergistic and multidimensional pathways by which to intervene. For older women of color living with HIV, FI presents a multidimensional challenge and highlights a “Gordian knot” of interactions between aging and living with HIV. For example, HIV accelerates aging-related inflammation that impacts the central nervous system, leading to neurocognitive decline.
-
Defining the cellular and viral factors underlying HIV latency at the single cell level
Defining the cellular and viral factors underlying HIV latency at the single cell level
Abstract
Latently infected CD4+ T cells, thought to be the main barrier to HIV cure, are indistinguishable from uninfected cells and are exceedingly rare, rendering the study of HIV latency in vivo particularly challenging. The development of more tractable systems such as in vitro primary cell models of latency has greatly advanced our understanding of the establishment, maintenance and reactivation of HIV latency, since these models permit higher infection frequencies and some employ reporter viruses to readily distinguish latent and productively infected populations.
-
Locating perceptions of HIV acquisition and transmission risks among people who inject drugs in West Virginia
Locating perceptions of HIV acquisition and transmission risks among people who inject drugs in West Virginia
Abstract
West Virginia has some of the highest risk areas in the country for HIV transmission. Opioid use, particularly through injection, has risen dramatically in the state which also has the nation’s highest drug overdose death rate.